K. Zech

Publications137
h-index31
Citations2,766
Highly Influential Citations112
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • T. Bethke
  • 54 Publications, 1,583 Citations
  • G. Lahu
  • 71 Publications, 751 Citations
  • A. Huennemeyer
  • 28 Publications, 409 Citations
  • W. Voelter
  • 638 Publications, 8,652 Citations
  • Publications
  • Influence
Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes.
Cultured human hepatocytes are a valuable in vitro system for evaluating new molecular entities as inducers of cytochrome P450 (P450) enzymes. The present study summarizes data obtained from 62… Expand
  • 329
  • 24
  • PDF
Pharmacokinetics of pantoprazole in man.
The proton pump inhibitor pantoprazole is a substituted benzimidazole sulphoxide for the treatment of acid-related gastrointestinal diseases such as reflux esophagitis, duodenal and gastric ulcers.… Expand
  • 120
  • 9
Determination of selected pyrimidines, purines and their metabolites in serum and urine by reversed-phase ion-pair chromatography.
The qualitative and quantitative determination of selected pyrimidines, purines and azapurines and their metabolites by reversed-phase ion-pair high-performance liquid chromatography, using… Expand
  • 89
  • 8
Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model
Background:Roflumilast is an oral, selective phosphodiesterase (PDE)-4 inhibitor in development for the treatment of chronic obstructive pulmonary disease (COPD). Both roflumilast and its metabolite… Expand
  • 30
  • 6
  • PDF
Pharmacokinetics of [14C]Ciclesonide After Oral and Intravenous Administration to Healthy Subjects
BackgroundCiclesonide is a novel inhaled corticosteroid developed for the treatment of asthma.ObjectiveTo investigate the extent of oral absorption and bioavailability of ciclesonide referenced to an… Expand
  • 100
  • 5
A novel screening strategy to identify ABCB1 substrates and inhibitors
We tested the hypothesis whether data on ABCB1 ATPase activity and passive permeability can be used in combination to identify ABCB1 substrates and inhibitors. We determined passive permeability… Expand
  • 54
  • 5
The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue.
Ciclesonide (CIC) is an inhaled glucocorticosteroid. This study aimed to identify esterases involved in the metabolism of CIC to the active metabolite desisobutyryl-ciclesonide (des-CIC), and to… Expand
  • 62
  • 4
Steady-State Pharmacokinetics of Roflumilast and Roflumilast N-Oxide in Patients with Mild and Moderate Liver Cirrhosis
BackgroundRoflumilast and its primary N-oxide metabolite are targeted Phosphodiesterase 4 (PDE4) inhibitors with similar in vivo potency. Roflumilast is being developed for the treatment of… Expand
  • 33
  • 4
Risk‐Benefit Value of Inhaled Glucocorticoids: A Pharmacokinetic/ Pharmacodynamic Perspective
Inhaled glucocorticoids induce therapeutic and adverse systemic effects via the same types of receptors. Analysis of the pharmacokinetic/pharmacodynamic parameters of inhaled glucocorticoids… Expand
  • 82
  • 3
Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration
Purpose: To investigate distribution and excretion of mangafodipir (MnDPDP, Teslascan) in the rat and dog. Material and Methods: Formulations of either 14C-MnDPDP or 54MnDPDP were injected… Expand
  • 48
  • 3